Otros idiomas INVO Bioscience, Inc.

Acciones

INVO

US44984F4019

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 21/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,9143 ^USD	-1,58 %		-18,37 %	-32,27 %

16/04	INVO Bioscience, Inc. informa de los resultados del año completo finalizado el 31 de diciembre de 2023	CI
2023	NAYA Biosciences Inc. anuncia la publicación de nuevos datos de su anticuerpo biespecífico Flex-NK dirigido a CD38 en el Blood Journal de la Sociedad Americana de Hematología	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

INVO Reports Record First Quarter 2024 Financial Results	15/05
Exploring Emerging Companies with Key Developments Garnering Attention: INBS, INVO, VTAK, RCAT, GCTK	22/04
Top Premarket Decliners	18/04
Sector Update: Health Care Stocks Retreating Late Afternoon	17/04
Top Midday Gainers	17/04
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	17/04
Top Premarket Gainers	17/04
INVO Reports Fourth Quarter and Full Year 2023 Financial Results	16/04
INVO Bioscience : Reports Fourth Quarter and Full Year 2023 Financial Results - Form 8-K	16/04
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC	08/04
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	05/04
INVO Bioscience : Private Placement - Form 8-K	01/04
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors	17/01
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.	29/12
INVO Bioscience : Submission of Matters to a Vote of Security Holders - Form 8-K	28/12
NAYA Biosciences Announces Publication Of New Data For Its CD38-Targeted Flex-NK Bispecific Antibody in The American Society of Hematology s Blood Journal	12/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas INVO Bioscience, Inc.

Acciones

INVO

US44984F4019

Otros idiomas

Filtros